Get the Stockscreener App
70.34
0.29%
0.20
After Hours:
70.34
Tarsus Pharmaceuticals Inc stock is traded at $70.34, with a volume of 559.04K.
It is up +0.29% in the last 24 hours and up +42.50% over the past month.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
See More
Previous Close:
$70.14
Open:
$70
24h Volume:
559.04K
Relative Volume:
0.83
Market Cap:
$2.97B
Revenue:
$17.39M
Net Income/Loss:
$-135.89M
P/E Ratio:
-15.16
EPS:
-4.64
Net Cash Flow:
$-123.00M
1W Performance:
+3.88%
1M Performance:
+42.50%
6M Performance:
+51.50%
1Y Performance:
+96.98%
1-Day Range:
$66.44
$71.15
1-Week Range:
$66.44
$71.15
52-Week Range:
$35.34
$71.15
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Name
Tarsus Pharmaceuticals Inc
Sector
Industry
Phone
(949) 409-9820
Address
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
70.34 | 2.96B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-27-25 | Resumed | H.C. Wainwright | Buy |
| Nov-20-23 | Initiated | Goldman | Neutral |
| Jul-18-23 | Initiated | William Blair | Outperform |
| May-18-23 | Initiated | Guggenheim | Buy |
| Aug-01-22 | Initiated | Barclays | Overweight |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-23-21 | Initiated | Oppenheimer | Outperform |
| Nov-10-20 | Initiated | BofA Securities | Buy |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Ladenburg Thalmann | Buy |
| Nov-10-20 | Initiated | Raymond James | Strong Buy |
View All
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
Can Tarsus Pharmaceuticals Inc. stock resist market sell offsWeekly Market Outlook & Daily Volume Surge Trade Alerts - newser.com
Is Tarsus Pharmaceuticals Inc. building a consolidation base2025 Pullback Review & Weekly Market Pulse Alerts - newser.com
How sentiment analysis helps forecast Tarsus Pharmaceuticals Inc.Market Risk Report & Reliable Trade Execution Plans - newser.com
Full technical analysis of Tarsus Pharmaceuticals Inc. stockMarket Activity Summary & Smart Allocation Stock Tips - newser.com
Will Tarsus Pharmaceuticals Inc. stock deliver shareholder valueJuly 2025 Reactions & Capital Efficient Trading Techniques - newser.com
Tarsus Pharmaceuticals Hits New 52-Week High of $68.00 - Markets Mojo
Tarsus Pharmaceuticals Experiences Evaluation Revision Amid Strong Market Performance Indicators - Markets Mojo
Should you hold or exit Tarsus Pharmaceuticals Inc. nowWeekly Market Outlook & Accurate Intraday Trade Tips - newser.com
Will Tarsus Pharmaceuticals Inc. benefit from macro trendsWeekly Trade Recap & Daily Profit Maximizing Tips - newser.com
Tarsus Pharmaceuticals Achieves 101.95% Annual Growth, Solidifying Status as Multibagger Stock - Markets Mojo
Using data models to predict Tarsus Pharmaceuticals Inc. stock movementWeekly Stock Report & Weekly Setup with High ROI Potential - newser.com
Applying big data sentiment scoring on Tarsus Pharmaceuticals Inc.Breakout Watch & Safe Capital Investment Plans - newser.com
Trend analysis for Tarsus Pharmaceuticals Inc. this weekInsider Buying & Breakout Confirmation Trade Signals - newser.com
Tarsus Pharmaceuticals Hits New 52-Week High of $70.58 - Markets Mojo
BofA Ups Price Target on Tarsus Pharmaceuticals to $85 From $80 - MarketScreener
Weiss Ratings Reaffirms "Sell (D-)" Rating for Tarsus Pharmaceuticals (NASDAQ:TARS) - MarketBeat
Why Tarsus Pharmaceuticals (TARS) Is Up 21.6% After Xdemvy’s Uptake and New Trial Announcements—And What's Next - Yahoo Finance
Tarsus Pharmaceuticals stock hits all-time high at 69.6 USD By Investing.com - Investing.com Nigeria
Tarsus Pharmaceuticals stock hits all-time high at 69.6 USD - Investing.com
Tarsus Pharmaceuticals Hits New 52-Week High of $69.49 - Markets Mojo
Tarsus Pharmaceuticals Inc Stock Analysis and ForecastPrice Momentum Alerts & Investment Recommendations You Can Trust - earlytimes.in
Tarsus Pharmaceuticals Hits Day High with 10.89% Surge in Stock Price - Markets Mojo
Tarsus Pharmaceuticals Hits New 52-Week High of $65.97, Surges 101% - Markets Mojo
Tarsus Pharmaceuticals (NASDAQ:TARS) Reaches New 52-Week HighWhat's Next? - MarketBeat
Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last? - Yahoo Finance
How Tarsus Pharmaceuticals Inc. stock reacts to inflationary pressures2025 Analyst Calls & Consistent Profit Trade Alerts - newser.com
How Tarsus Pharmaceuticals Inc. stock trades before earningsEarnings Recap Summary & Consistent Profit Trading Strategies - newser.com
Is Tarsus Pharmaceuticals Inc. forming a bottoming baseJuly 2025 Opening Moves & Advanced Technical Signal Analysis - newser.com
Why Tarsus Pharmaceuticals Inc. stock attracts high net worth investorsJuly 2025 Opening Moves & Safe Entry Zone Tips - newser.com
Tarsus Pharmaceuticals (NASDAQ:TARS) Trading 9.6% HigherTime to Buy? - MarketBeat
Tarsus Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
TARS Shares Roar Back: Explore The Surge - timothysykes.com
BofA Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $80 - 富途牛牛
Tarsus Pharmaceuticals Hits New 52-Week High of $59.77 - Markets Mojo
Tarsus Pharmaceuticals Hits Day High with Strong 7.29% Intraday Surge - Markets Mojo
Lyme Disease Market Growth Highlighted by Pipeline Advances and Expanding Patient Population | DelveInsight - GlobeNewswire Inc.
Using Bollinger Bands to evaluate Tarsus Pharmaceuticals Inc.Watch List & Fast Gaining Stock Strategy Reports - newser.com
Tarsus Pharmaceuticals stock hits 52-week high at 59.76 USD By Investing.com - Investing.com Australia
Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):